title: The role of short daily hemodialysis in the control of hyperphosphatemia, secondary hyperparathyroidism and anemia.
abstract: BACKGROUND
  Hyperphosphatemia, secondary hyperparathyroidism (SHPT) and anemia are common secondary complications in hemodialysis patients with end-stage renal disease (ESRD). Compared with conventional hemodialysis (CHD), short daily hemodialysis (sDHD) has been found to be more effective in patients with ESRD. The objective of this study was to determine whether sDHD could improve hyperphosphatemia, SHPT and anemia in patients with ESRD.
  
  
  METHODS
  Twenty-seven patients (11 women and 16 men, 46.8 ± 13.4 years old) were switched from CHD to sDHD. All hematologic parameters were measured prior to the switch (baseline), at 3 months after the switch (sDHD(1)) and at 6 months after the switch (sDHD(2)).
  
  
  RESULTS
  The serum phosphate decreased from 2.54 ± 0.32 mmol/L at baseline to 2.15 ± 0.36 mmol/L (p < 0.001) at sDHD(1) and 1.97 ± 0.33 mmol/L (p < 0.001) at sDHD(2). Calcium-phosphate product decreased from 5.18 ± 1.24 mmol(2)/L(2) at baseline to 4.20 ± 0.71 mmol(2)/L(2) (p < 0.001) at sDHD(1) and 4.02 ± 0.83 mmol(2)/L(2) (p < 0.001) at sDHD(2). The serum PTH levels decreased from 223.9 ± 124.7 pmol/L at baseline to 196.3 ± 101.3 pmol/L (p < 0.05) at sDHD(2). The hemoglobin concentration increased significantly from CHD to sDHD. However, the requirement for erythropoietin (EPO) dose decreased from 6847.8 ± 1057.3 u/week at baseline to 5869.6 ± 1094.6 u/week (p < 0.05) at sDHD(2).
  
  
  CONCLUSIONS
  sDHD may decrease serum phosphate, calcium-phosphate product and PTH, increase hemoglobin levels and decrease exogenous EPO dose requirements compared with CHD in hemodialysis patients.
authors.affiliation: Department of Nephrology, Qilu Hospital Affiliated to Shandong University, 107 Wenhuaxi road, Jinan, 250012, China.
authors.forename: Jie-Long
authors.initials: JL
authors.lastname: Jiang
authors.forename: Wei
authors.initials: W
authors.lastname: Ren
authors.forename: Yan
authors.initials: Y
authors.lastname: Li
authors.forename: Guang-Yi
authors.initials: GY
authors.lastname: Liu
authors.forename: Cai-Ping
authors.initials: CP
authors.lastname: Zhou
authors.forename: Ke-Liang
authors.initials: KL
authors.lastname: Su
authors.forename: Wei
authors.initials: W
authors.lastname: Chen
authors.forename: Ke
authors.initials: K
authors.lastname: Wang
authors.forename: Li-Jun
authors.initials: LJ
authors.lastname: Ni
authors.forename: Zhao
authors.initials: Z
authors.lastname: Hu
mesh_terms: D000328:Adult; D000368:Aged; D000740:Anemia / Q000097:blood / Q000209:etiology / Q000517:prevention & control*; D002130:Calcium Phosphates / Q000097:blood; D004921:Erythropoietin / Q000008:administration & dosage; D005260:Female; D006304:Health Status; D006454:Hemoglobins / Q000378:metabolism; D006801:Humans; D006962:Hyperparathyroidism, Secondary / Q000097:blood / Q000209:etiology / Q000517:prevention & control*; D054559:Hyperphosphatemia / Q000097:blood / Q000209:etiology / Q000517:prevention & control*; D007676:Kidney Failure, Chronic / Q000097:blood / Q000150:complications / Q000628:therapy*; D008297:Male; D008603:Mental Health; D008875:Middle Aged; D010281:Parathyroid Hormone / Q000097:blood; D011788:Quality of Life; D006435:Renal Dialysis / Q000009:adverse effects / Q000379:methods*
chemical_list: D002130:Calcium Phosphates; D006454:Hemoglobins; D010281:Parathyroid Hormone; D004921:Erythropoietin; C020243:calcium phosphate